Analysts expect Aldeyra Therapeutics to report a Q3 2026 consensus net loss of $0.11 per share on estimated revenue of $1.25 million, with the stock currently trading near $0.63 against a $6.60 average price target.

The primary focus for investors remains the status of the Formal Dispute Resolution Request (FDRR) submitted to the FDA to appeal the rejection of lead candidate reproxalap for dry eye disease.

Following a third Complete Response Letter in March 2026, the company has implemented aggressive cost-cutting measures and shifted its focus almost entirely toward regulatory escalation.

Investors are closely monitoring the company's remaining cash runway, which management recently indicated would fund operations into 2028 despite the current lack of a commercialized product.